Program for Appropriate Technology in Health-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Program for Appropriate Technology in Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013220
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Program for Appropriate Technology in Health (PATH) is a healthcare organization that offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. The organization offers HIV and AIDS, influenza, malaria and tuberculosis care services. It develops diagnostics for HIV and other sexually transmitted infections, malaria, tuberculosis, epidemic and emerging diseases, women’s cancers, non communicable diseases, diabetes and neglected tropical diseases. PATH caters to governments, donors, and multilateral organizations. PATH collaborates with innovators, public and private-sector partners, governments, communities, and civil society groups to identify and produce devices and tools. The organization has operations in Belgium, Cambodia, China, Congo, Ethiopia, France, Ghana, India, Kenya, the US, and others. PATH is headquartered in Seattle, Washington, the US.

Program for Appropriate Technology in Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2011 to YTD 2017 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 12
Radboudumc and iMM Lisboa Enters Into Partnership with PATH 13
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 14
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 15
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 16
Novavax Amends Co-Development Agreement With PATH 17
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 18
Liquidia Technologies Extends Co-Development Agreement With PATH 19
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 20
Novavax Enters Into Co-Development Agreement With PATH 21
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 23
Liquidia Technologies Enters Into An Agreement With Path Malaria Vaccine 24
Program for Appropriate Technology in Health – Key Competitors 25
Program for Appropriate Technology in Health – Key Employees 26
Program for Appropriate Technology in Health – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Key Facts 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Program for Appropriate Technology in Health, Deals By Therapy Area, 2011 to YTD 2017 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2011 to YTD 2017 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 12
Radboudumc and iMM Lisboa Enters Into Partnership with PATH 13
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 14
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 15
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 16
Novavax Amends Co-Development Agreement With PATH 17
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 18
Liquidia Technologies Extends Co-Development Agreement With PATH 19
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 20
Novavax Enters Into Co-Development Agreement With PATH 21
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 23
Liquidia Technologies Enters Into An Agreement With Path Malaria Vaccine 24
Program for Appropriate Technology in Health, Key Competitors 25
Program for Appropriate Technology in Health, Key Employees 26
Program for Appropriate Technology in Health, Other Locations 27
Program for Appropriate Technology in Health, Subsidiaries 28
Program for Appropriate Technology in Health, Joint Venture 28

★海外企業調査レポート[Program for Appropriate Technology in Health-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lexicon Pharmaceuticals Inc (LXRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program …
  • Teva Pharmaceutical Industries Ltd (TEVA)-医療機器分野:企業M&A・提携分析
    Summary Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company off …
  • The Beacon Insurance Company Limited:企業の戦略・SWOT・財務分析
    The Beacon Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary The Beacon Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • CYBG PLC:企業の戦略・SWOT・財務情報
    CYBG PLC - Strategy, SWOT and Corporate Finance Report Summary CYBG PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • PricewaterhouseCoopers LLP:企業の戦略的SWOT分析
    PricewaterhouseCoopers LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Inretail Peru Corp.:企業の戦略的SWOT分析
    Inretail Peru Corp. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Ameriprise Financial, Inc.:戦略・SWOT・企業財務分析
    Ameriprise Financial, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ameriprise Financial, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • GenomicTree Co Ltd (228760):企業の製品パイプライン分析
    Summary GenomicTree Co Ltd (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung …
  • Fletcher Building Ltd:戦略・SWOT・企業財務分析
    Fletcher Building Ltd - Strategy, SWOT and Corporate Finance Report Summary Fletcher Building Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bonterra Energy Corp (BNE)-石油・ガス分野:企業M&A・提携分析
    Summary Bonterra Energy Corp. (Bonterra) is an oil and gas company. It acquires and develops producing or undeveloped oil and gas properties. It produces crude oil, natural gas and natural gas liquids. The company principally operates in the provinces of Alberta, British Columbia and Saskatchewan in …
  • IDFC Ltd (IDFC):企業の財務・戦略的SWOT分析
    IDFC Ltd (IDFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Bawag Psk
    Bawag Psk - Strategy, SWOT and Corporate Finance Report Summary Bawag Psk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Merrimack Pharmaceuticals Inc (MACK):製薬・医療:M&Aディール及び事業提携情報
    Summary Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (mark …
  • Aluminum Corporation of China Ltd:企業の戦略・SWOT・財務情報
    Aluminum Corporation of China Ltd - Strategy, SWOT and Corporate Finance Report Summary Aluminum Corporation of China Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • National Fuel Gas Company:企業の戦略・SWOT・財務情報
    National Fuel Gas Company - Strategy, SWOT and Corporate Finance Report Summary National Fuel Gas Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Takeda Pharmaceutical Co Ltd (4502):企業の財務・戦略的SWOT分析
    Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Celcuity Inc (CELC):企業の製品パイプライン分析
    Summary Celcuity Inc (Celcuity) is a cellular analysis company that develops companion diagnostic tests to identify new patient populations for targeted therapies. The company’s CELx signaling function diagnostic platform utilizes a patient’s living tumor cells to identify the specific abnormal cell …
  • Exor N.V
    Exor N.V - Strategy, SWOT and Corporate Finance Report Summary Exor N.V - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Feldan Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Feldan Therapeutics Inc (Feldan), formerly Feldan Bio Inc, is a biotechnology company with focus on the discovery, development, manufacture and marketing of recombinant proteins. The company developed a peptide-based technology platform, the Feldan Shuttle for intracellular delivery of prote …
  • B&N Bank (Joint-Stock Company):企業の戦略・SWOT・財務情報
    B&N Bank (Joint-Stock Company) - Strategy, SWOT and Corporate Finance Report Summary B&N Bank (Joint-Stock Company) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆